Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.59 |
| ▸ | HTT | P42858 | 4/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | ATM | Q13315 | 3/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 8/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 7/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2274582 | 1.00 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2HTTNPSR1LMNA | |
| SCHEMBL8844390 | 0.83 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2HTTNPSR1LMNA | |
| SCHEMBL3188566 | 0.82 | ALDH1A1 (0.51) | ALDH1A1HTTLMNAHPGDTDP1 | |
| SCHEMBL10378891 | 0.82 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2HTTLMNAMEN1 | |
| SCHEMBL3188558 | 0.82 | ALDH1A1 (0.51) | ALDH1A1HTTLMNAHPGDTDP1 | |
| SCHEMBL2271314 | 0.82 | MAPT (0.61) | ALDH1A1SMN1; SMN2PKMHPGDTDP1 | |
| SCHEMBL2271311 | 0.82 | MAPT (0.61) | ALDH1A1SMN1; SMN2PKMHPGDTDP1 | |
| SCHEMBL10378889 | 0.82 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2HTTLMNAMEN1 | |
| SCHEMBL15784370 | 0.81 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2HTTNPSR1LMNA | |
| SCHEMBL3187174 | 0.81 | NFE2L2 (0.59) | ALDH1A1SMN1; SMN2LMNAHPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989633-B2 | 4-Chromenonyl-1,4-dihydropyridines and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-02 | — | — | US | disclosed |
| US-7989633-B2 | 4-Chromenonyl-1,4-dihydropyridines and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-02 | — | — | US | disclosed |
| US-20100022484-A1 | 4-Chromenonyl-1,4-dihydropyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022484-A1 | 4-Chromenonyl-1,4-dihydropyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| WO-2007100295-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | TORRENT PHARMACEUTICALS LTD (IN) | 2007-09-07 | — | — | WO | disclosed |
| EP-0168037-B1 | 1-6-NAPHTHYRIDIN-2(1H)-ONES USEFUL AS CARDIOTONICS | STERLING DRUG INC. (US) | 1990-02-07 | — | — | EP | disclosed |
| EP-0168037-A2 | 1-6-Naphthyridin-2(1H)-ones useful as cardiotonics | STERLING DRUG INC. (US) | 1986-01-15 | — | — | EP | disclosed |
| US-4560691-A | 5-(Phenyl)-1,6-naphthyridin-2(1H)-ones, their cardiotonic use and preparation | STERLING DRUG INC. (US) | 1985-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022484-A1 | 4-Chromenonyl-1,4-dihydropyridines and their use | RYR1, RYR2, CACNA1S | ALDH1A1 542/4885SMN1; SMN2 2193/4885HTT 1573/4885 |
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | EDNRA, EDNRB, AGTR1 | ALDH1A1 892/4885SMN1; SMN2 4868/4885HTT 4179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.